Other studies have confirmed that DEX activates CD8+ and CD4+ T cells and induces anti-tumor immune responses via in vitro CD80-mediated exosomes and in vivo endogenous IL-2 (47, 48). This evidence concerns the gene CD8A and neoplasm.